7.02

3.17% -0.23

After Hours: 6.80 -0.22 -3.13%

Decoy Therapeutics Inc (DCOY)

Overview News Price History Discussions Forecast

Decoy Therapeutics Inc stock is traded at $7.02, with a volume of 9,997. It is down -3.17% in the last 24 hours and up +6.20% over the past month. Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.

Previous Close:

$7.25

Open:

24h Volume:

9,997

Relative Volume:

0.05

Market Cap:

$3.73M

Revenue:

Net Income/Loss:

$-13.03M

P/E Ratio:

-0.0566

EPS:

-124.0371

Net Cash Flow:

$-6.53M

1W Performance:

-2.36%

1M Performance:

+6.20%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$6.7506

$7.30

1-Week Range:

$6.0501

$8.33

52-Week Range:

$4.3201

$16.92

Decoy Therapeutics Inc Stock (DCOY) Company Profile

Name

Decoy Therapeutics Inc

Sector

Healthcare (1094)

Industry

Biotechnology (615)

Phone

346-772-0346

Address

2450 HOLCOMBE BLVD, HOUSTON

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

DCOY's Discussions on Twitter

Compare DCOY vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DCOY Decoy Therapeutics Inc	7.02	3.86M	0	-13.03M	-6.53M	-124.04
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.94	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.59	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-23-26	Initiated	Ladenburg Thalmann	Buy
Apr-27-20	Initiated	Ladenburg Thalmann	Buy

Decoy Therapeutics Inc Stock (DCOY) Latest News

Jul 03, 2026

DCOYDecoy Therapeutics Inc Latest SEC Filings - Finviz

Jul 03, 2026

DCOY Q3 2024 Earnings: Narrower-than-Expected Loss Fails to Stem Stock DeclineRevenue Growth Report - dars.gov.et

Jul 03, 2026

Jul 01, 2026

Decoy stock rises after announcing up to $21 million private placement financing - MSN

Jul 01, 2026

Jun 30, 2026

Decoy Therapeutics Inc. Financial Disclosures & Filings - TradingView

Jun 30, 2026

Crude Oil Gains 2%; Comcast Shares Spike Higher - Sahm

Jun 30, 2026

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
HANISH ARNOLD C	Director	Dec 30 '25	Sale	0.64	12	8	0
HANISH ARNOLD C	Director	Nov 20 '25	Buy	0.75	5,000	3,740	5,015
Rosenblum Mark J	Exec VP Finance, CFO	Nov 20 '25	Buy	0.80	20,000	16,000	20,177

Decoy Therapeutics Inc (DCOY)

Decoy Therapeutics Inc Stock (DCOY) Company Profile

Compare DCOY vs VRTX, REGN, ARGX, ALNY, RVMD

Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades

Decoy Therapeutics Inc Stock (DCOY) Latest News

DCOYDecoy Therapeutics Inc Latest SEC Filings - Finviz

DCOY Q3 2024 Earnings: Narrower-than-Expected Loss Fails to Stem Stock DeclineRevenue Growth Report - dars.gov.et

Decoy stock rises after announcing up to $21 million private placement financing - MSN

Decoy Therapeutics Inc. Financial Disclosures & Filings - TradingView

Crude Oil Gains 2%; Comcast Shares Spike Higher - Sahm

Market Movers | Winners: TRNR, DCOY, ATLN | Losers: BJDX, EVMN, CELZ - Trefis

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Decoy Therapeutics secures $3.5M PIPE financing; shares surge - MSN

User - The Chronicle-Journal

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

DCOY Stock Nearly Doubled In Value Today – What’s Driving This Mega Rally? - Asianet Newsable

Trending Stocks Today | Universe Pharmaceuticals Soars 333.17% - Moomoo

DCOY Stock Explodes Higher As Volatile Biotech Trading Heats Up - StocksToTrade

Decoy Stock Rises After Announcing Up to $21 Million Private Placement Financing - Benzinga

Decoy Therapeutics Secures Up to $21 Million PIPE Financing to Advance Multi-Antiviral Clinical Trials - Minichart

DCOY Stock Whipsaws As Traders Eye Volatile Setup - timothysykes.com

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Morning Market Movers: UPC, DCOY, CMSA, LRMR See Big Swings - RTTNews

Decoy Therapeutics Secures PIPE Financing to Advance Trials - TipRanks

Decoy Therapeutics Raises $3.5 Million in Private Placement at $5.91, Adds Milestone Warrants - TradingView

Decoy Therapeutics (NASDAQ: DCOY) lines up $21M milestone-based PIPE funding - Stock Titan

$Decoy Therapeutics (DCOY.US)$ - Moomoo

Decoy Therapeutics Inc. Actuals & Estimates (FWB:FP11) - TradingView

Decoy Therapeutics Inc. Actuals & Estimates (BOATS:DCOY) - TradingView

Decoy Therapeutics secures $3.5M financing with investor By Investing.com - Investing.com Australia

DECOY THERAPEUTICS, INC. ANNOUNCES UP TO $21 MILLION PRIVATE PLACEMENT FINANCING - Moomoo

Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing - Lake Geneva News

Decoy Therapeutics Inc. Actuals & Estimates (GETTEX:FP11) - TradingView

Decoy Therapeutics Inc. Actuals & Estimates (MUN:FP11) - TradingView

Decoy Therapeutics Inc. Actuals & Estimates (NASDAQ:DCOY) - TradingView

[EFFECT] Decoy Therapeutics Inc. SEC Filing - Stock Titan

Decoy Therapeutics (DCOY) Stock Forum and Discussion - Moomoo

Decoy Therapeutics (NASDAQ: DCOY) files S-1 for 808,000-share equity line resale - Stock Titan

Decoy Therapeutics: David Arthur Completing His Service on the Board >DCOY - Moomoo

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London - Morningstar

[RW] Decoy Therapeutics Inc. SEC Filing - Stock Titan

DCOY SEC FilingsDECOY THERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan

DCOY Q3 2024 Earnings: Narrower-Than-Expected Losses Mask Pipeline UncertaintyRevenue Report - dars.gov.et

DCOY | Decoy Therapeutics Inc. Common Executive Compensation - Quiver Quantitative

Decoy Therapeutics (DCOY) details 2026 director, pay and auditor votes - Stock Titan

DCOY Q3 2024 Earnings: Narrower-Than-Expected Loss Fails to Offset Investor ConcernsTrough Earnings Signal - dars.gov.et

Decoy Therapeutics nominates Patricia Gauthier to board - Investing.com UK

Decoy Therapeutics nominates Patricia Gauthier to board By Investing.com - Investing.com South Africa

Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors - PR Newswire

hVIVO win with Decoy Therapeutics signals shift towards broader contract research market, says broker - Proactive Investors

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Ca - GuruFocus

hVIVO signs consultancy deal with antiviral developer Decoy Therapeutics - Proactive Investors

hVIVO to support Decoy Therapeutics respiratory antiviral development - Vox Markets

hVIVO signs consultancy deal with Decoy Therapeutics By Investing.com - Investing.com Canada

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic - Financial Times

Decoy Therapeutics Inc Stock (DCOY) Financials Data

Revenue

Net Income

Cash Flow

EPS

Decoy Therapeutics Inc Stock (DCOY) Insider Trading

Similar to DCOY